Posts by Constance

6 days ago

Egle Therapeutics Initiates Phase 1 Healthy Volunteer Study of EGL-003, a Next Generation Treg IL-2 Agonist for Atopic Dermatitis

Paris, France, Dec. 1, 2025 – Egle Therapeutics SAS (Egle), a clinical-stage biotechnology company developing precision medicines that modulate regulatory T cells (Tregs) to restore immune balance, today announced dosing…

4 months ago

International Congress of Immunology – IUIS 2025

Dates : 17 – 22 August 2025 Location : Vienna, Austria Several representatives from our laboratory will have the pleasure of participating in the 19th International Congress of Immunology, organized…

6 months ago

Egle Therapeutics to Present New Preclinical Data EGL-003, a Novel IL-2 Mutein for Selective Expansion of Tregs to Restore Immune Balance with Best-in-class Potential, at EULAR 2025 Congress

Paris, France, June 10th 2025 – Egle Therapeutics, a clinical-stage biotechnology company developing therapies targeting regulatory T cells (Tregs) for immuno-oncology and autoimmune diseases, today announced a poster presentation at…

6 months ago

Egle Therapeutics to Present Clinical Trial Progress Poster on Phase I/II EGL-121 Study for EGL-001 at 2025 ASCO Annual Meeting

Egle Therapeutics, a clinical-stage biotechnology company developing therapies targeting regulatory T cells (Tregs) for immuno-oncology and autoimmune diseases, today announced a poster presentation at the upcoming 2025 American Society of…

8 months ago

Egle Therapeutics to highlight novel preclinical findings for regulatory T cells targeting programs EGL-001 and EGL-002 with poster presentations at the 2025 AACR Annual Meeting

Egle Therapeutics, a clinical-stage biotechnology company developing therapies targeting regulatory T cells (Tregs) for immuno-oncology and autoimmune diseases, will present two posters at the American Association for Cancer Research Annual…

8 months ago

Posts by Constance

Egle Therapeutics Initiates Phase 1 Healthy Volunteer Study of EGL-003, a Next Generation Treg IL-2 Agonist for Atopic Dermatitis

International Congress of Immunology – IUIS 2025

Egle Therapeutics to Present New Preclinical Data EGL-003, a Novel IL-2 Mutein for Selective Expansion of Tregs to Restore Immune Balance with Best-in-class Potential, at EULAR 2025 Congress

Egle Therapeutics to Present Clinical Trial Progress Poster on Phase I/II EGL-121 Study for EGL-001 at 2025 ASCO Annual Meeting

Egle Therapeutics to highlight novel preclinical findings for regulatory T cells targeting programs EGL-001 and EGL-002 with poster presentations at the 2025 AACR Annual Meeting

American Society of Clinical Oncology – Annual Congress 2025

European Alliance of Associations for Rheumatology – Annual Congress 2025

Bio€quity Europe 2025

American Association for Cancer Research – Annual Meeting 2025